Equillium (EQ) Amortization of Deferred Charges (2020 - 2023)
Equillium (EQ) posted quarterly Amortization of Deferred Charges of $150000.0 for Q2 2023, up 188.46% year-over-year from $52000.0 in Q2 2022, and up 400.0% quarter-over-quarter from $30000.0 in Q1 2023.
Powered by 
Analysis
Equillium (EQ) Amortization of Deferred Charges (2020 - 2023) Analysis & Trends
Equillium (EQ) has reported Amortization of Deferred Charges for 4 consecutive years, with $150000.0 the latest figure, recorded in Q2 2023.
- In Q2 2023, Amortization of Deferred Charges rose 188.46% year-over-year to $150000.0; the TTM figure through Dec 2023 stood at $180000.0 (down 11.33% YoY), while the FY2023 annual figure was $180000.0, down 11.33% from the prior year.
- Amortization of Deferred Charges rose to $150000.0 in Q2 2023 per EQ's latest filing, from $30000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $150000.0 in Q2 2023 and bottomed at $30000.0 in Q1 2023.
- Historically, Amortization of Deferred Charges has averaged $62857.1 across 4 years, with a median of $59000.0 in 2021.
- On a YoY basis, Amortization of Deferred Charges climbed as much as 188.46% in 2023 and fell as far as 37.5% in 2023.
- Equillium's Amortization of Deferred Charges stood at $65000.0 in 2020, then decreased by 15.38% to $55000.0 in 2021, then declined by 7.27% to $51000.0 in 2022, then jumped by 194.12% to $150000.0 in 2023.
- Business Quant data shows EQ's Amortization of Deferred Charges at $150000.0 in Q2 2023, $30000.0 in Q1 2023, and $51000.0 in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Equillium | 249.33 Mn | 249.33 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | 150,000.00 |
| Mar 31, 2023 | 30,000.00 |
| Dec 31, 2022 | 51,000.00 |
| Sep 30, 2022 | 52,000.00 |
| Jun 30, 2022 | 52,000.00 |
| Mar 31, 2022 | 48,000.00 |
| Dec 31, 2021 | 55,000.00 |
| Sep 30, 2021 | 56,000.00 |
| Jun 30, 2021 | 62,000.00 |
| Mar 31, 2021 | 64,000.00 |
| Dec 31, 2020 | 65,000.00 |
| Sep 30, 2020 | 65,000.00 |
| Jun 30, 2020 | 65,000.00 |
| Mar 31, 2020 | 65,000.00 |